Results 221 to 230 of about 15,790 (257)

Prognostic factors of early recurrence after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. [PDF]

World J Clin Cases
Chen CY, Huang TH, Lee LW, Lung J, Ou YC, Hung CH, Chuang HC, Chen MC, Wang TY.   +8 more
europepmc   +1 more source

CD8 + T-cells restrict the development of peritoneal metastasis and support the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC). [PDF]

Sci Rep
Roth L, Huynh-Russo L, Heeb L, Ulugöl S, Freire Dos Santos R, Breuer E, Ungethüm U, Haberecker M, Pauli C, Koelzer V, Lehmann K, Gupta A.   +11 more
europepmc   +1 more source

Surgical and oncological outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma : A retrospective single center experience. [PDF]

Wien Klin Wochenschr
Müller C, Bergmann M, Stift A, Bachleitner-Hofmann T, Riss S.   +4 more
europepmc   +1 more source

Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy. [PDF]

Updates Surg
Jin S, Wei Y, Wang Q, Ju Y, Wang Z, Cheng Q, Li Z, Liu X, Wang K.   +8 more
europepmc   +1 more source

Multimodale Therapiekonzepte bei fortgeschrittenen abdominellen und retroperitonealen Tumorerkrankungen: Innovationen und ihr Stellenwert [PDF]

, 2017
Albertsmeier, Markus
core  

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Outcomes From a Tertiary Cancer Care Center in India. [PDF]

Cureus
Ray M, Pathak B, Venugopal R, Sonvane S.
europepmc   +1 more source

ASO Author Reflections: Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) of Extraperitoneal Abdominal Disease, a Likely Common Practice but Infrequently Reported. [PDF]

Ann Surg Oncol
Mangieri CW, Levine EA.
europepmc   +1 more source

Digital Health Intervention to Reduce Malnutrition Among Individuals With Gastrointestinal Cancer Receiving Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy: Feasibility, Acceptability, and Usability Trial.

JMIR Cancer
Lin YC, Hagen R, Powers BD, Dineen SP, Milano J, Hume E, Sprow O, Diaz-Carraway S, Permuth JB, Deneve J, Alishahi Tabriz A, Turner K.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Hypertherme intraperitoneale Chemotherapie

Der Chirurg, 2019
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are recognized as the standard of care for selected patients with peritoneal malignancies. A complete macroscopic cytoreduction is the basis for a successful multimodal treatment. The significance of intraperitoneal chemotherapy is still under discussion.
P Piso, H Leebmann
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Annals of Surgical Oncology, 2023
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality that aims to target the main site of tumor dissemination in ovarian cancer, the peritoneum, by combining the benefits of intraperitoneal chemotherapy with the synergistic effects of hyperthermia all during a single administration at the time of cytoreductive surgery. High-quality
Julia H, Gelissen, Naomi N, Adjei, Blair, McNamara, Levent, Mutlu, Justin A, Harold, Mitchell, Clark, Gary, Altwerger, Peter R, Dottino, Gloria S, Huang, Alessandro D, Santin, Masoud, Azodi, Elena, Ratner, Peter E, Schwartz, Vaagn, Andikyan   +13 more
openaire   +2 more sources